Bendamustine
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Bendamustine
- Pharmacist Assessment Report
- Bendamustine: Alkylating agent with purine-analog-like properties → mantle cell lymphoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Bendamustine: Alkylating agent with purine-analog-like properties → mantle cell lymphoma
One-Sentence Summary
Bendamustine is an alkylating chemotherapy drug that damages DNA in rapidly dividing B-cell lymphoma cells. The TxGNN model predicts it may be effective for mantle cell lymphoma, with 40 clinical trials and 20 publications compiled for this prediction, including several completed Phase 3 randomized trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | mantle cell lymphoma |
| TxGNN Prediction Score | 0.9963 |
| Evidence Level | L1 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, bendamustine is an alkylating agent with purine-analog-like properties. It produces DNA cross-links and triggers apoptosis in proliferating B-cell lymphoma cells.
Mantle cell lymphoma is a mature B-cell neoplasm, closely related to the other B-cell lymphomas that bendamustine is used for. Bendamustine plus rituximab (BR) is an established backbone regimen, and newer trials add BTK inhibitors (ibrutinib, acalabrutinib, orelabrutinib) on top of it. This fits the mechanistic logic behind the model’s prediction.
Clinical Trial Evidence
Trials that studied mantle cell lymphoma directly include several Phase 3 randomized studies. The most relevant are listed below.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00991211 | Phase 3 | Completed | 549 | First-line bendamustine + rituximab vs CHOP + rituximab in advanced indolent lymphoma and MCL (non-inferiority on progression-free survival) |
| NCT00877006 | Phase 3 | Completed | 447 | BRIGHT study: BR vs R-CHOP/R-CVP in first-line indolent NHL or MCL |
| NCT01776840 | Phase 3 | Completed | 523 | Ibrutinib added to BR in newly diagnosed MCL, patients 65 and older |
| NCT02972840 | Phase 3 | Active, not recruiting | 635 | Acalabrutinib + BR vs placebo + BR in untreated MCL |
| NCT06363994 | Phase 3 | Recruiting | 476 | Orelabrutinib + BR vs BR in treatment-naive MCL |
| NCT06084936 | Phase 3 | Recruiting | 182 | Glofitamab vs investigator’s choice (BR or R-lenalidomide) in relapsed/refractory MCL |
| NCT00891839 | Phase 2 | Completed | 45 | BR in relapsed/refractory MCL |
| NCT04115631 | Phase 2 | Active, not recruiting | 360 | BR with or without high-dose cytarabine and acalabrutinib in untreated MCL, age 70 or younger |
| NCT03834688 | Phase 2 | Completed | 33 | BR plus venetoclax in untreated MCL over age 60 |
| NCT00612183 | Phase 2 | Completed | 56 | Bendamustine in indolent B-cell NHL or MCL |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23433739 | 2013 | RCT | Lancet | Phase 3 non-inferiority trial: BR vs R-CHOP as first-line treatment in indolent and mantle-cell lymphomas |
| 24591201 | 2014 | RCT | Blood | BRIGHT study: BR vs R-CHOP/R-CVP in treatment-naive indolent NHL or MCL |
| 30811293 | 2019 | Cohort | J Clin Oncol | BRIGHT 5-year follow-up of BR vs R-CHOP/R-CVP |
| 35657079 | 2022 | RCT | N Engl J Med | Ibrutinib added to BR in untreated MCL |
| 40311141 | 2025 | RCT | J Clin Oncol | Acalabrutinib added to BR in untreated MCL |
| 41052510 | 2025 | RCT | Lancet | ENRICH: ibrutinib-rituximab vs immunochemotherapy (R-CHOP or BR) in untreated MCL, age 60 and older |
| 32126141 | 2020 | Cohort | Blood Adv | Rituximab/bendamustine then rituximab/cytarabine induction in transplant-eligible MCL |
| 40975105 | 2025 | Phase 2 | Lancet Haematol | Rituximab, bendamustine, cytarabine followed by venetoclax in older patients with high-risk MCL |
| 41132246 | 2025 | Review | HemaSphere | EHA-EU MCL network guidelines for diagnosis and treatment |
| 26755518 | 2016 | Review | J Clin Oncol | Review of MCL, noting bendamustine’s benefit in older patients |
India Market Information
Bendamustine single-ingredient injections are marketed in India. The data compiled for this report show 20 valid single-ingredient licences and none cancelled; the list below may be partial.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 99668 | Genmus 100mg Injection | Vial of 1 injection | Not recorded in local data |
| 129230 | Lymphtor 100mg Injection | Vial of 1 injection | Not recorded in local data |
| 28013 | Benzz 100mg Injection | Vial of 1 ml injection | Not recorded in local data |
| 30431 | Bendawel 100mg Injection | Vial of 1 injection | Not recorded in local data |
| 28278 | Bimode 100mg Injection | Vial of 20 ml injection | Not recorded in local data |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent) |
| Myelosuppression Risk | High; neutropenia, thrombocytopenia and anaemia are listed as concerns in the data compiled for this report |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC with differential, liver and renal function |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Conditions of concern: Liver failure, kidney disease, liver disease, gallbladder disease, thrombocytopenia, neutropenia, agranulocytosis, anaemia and macrocytic anaemia are flagged as contraindication-type concerns.
- Drug Interactions: 178 interactions were identified. Major-level examples include deferiprone and samarium (153Sm) lexidronam. Moderate-level examples include omeprazole, esomeprazole, cimetidine, caffeine, mercaptopurine, chloramphenicol and ticlopidine.
Please also refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several completed Phase 3 randomized trials (including NCT00991211 and NCT00877006) directly study bendamustine-based therapy in mantle cell lymphoma, backed by large randomized publications. Bendamustine is already marketed in India. Because it is a myelosuppressive cytotoxic drug with a long list of interactions and the local label text is missing, safety guardrails are needed.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India licence holders, and the approved indication text
- Detailed mechanism of action data
- A haematological monitoring and dose-adjustment plan, particularly for patients with hepatic or renal impairment
- Review of drug interaction risks for concomitant medicines, such as proton pump inhibitors and cimetidine
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.